Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab

Alfredo Pece, Claudio Azzolini, Maurizio Battaglia Parodi, Ferdinando Bottoni, Paola Danzi, Simone Donati, Ugo Introini, Vincenzo Pucci, Francesco Semeraro, Francesco Viola

Research output: Contribution to journalArticlepeer-review

Abstract

Age-related macular degeneration (AMD) is an irreversible pathology that is the principal cause of serious loss of central vision and legal blindness among people over 60 years of age. There are two forms of AMD: the dry, or atrophic form, and the wet, neovascular form. The latter is less frequent but is the cause of approximately 80-90% of cases of serious loss of vision in a short time period. Early diagnosis is therefore essential to permit intervention as promptly as possible. Currently, the most effective therapy for neovascular AMD uses the new class of anti-VEGF drugs, and ranibizumab is todays 'gold standard for this treatment. The Progetto LUCE (LUCE Project) consists of an advisory board of retinal disease specialists in Lombardy, Italy, whose task is to propose a consensus for the diagnosis, treatment and follow-up of neovascular AMD patients treated with ranibizumab on the basis of a review of the scientific evidence and Italian national health service regulations and the clinical experience of the advisory board members.

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalExpert Review of Ophthalmology
Volume7
Issue number3
DOIs
Publication statusPublished - Jun 2012

Keywords

  • age-related macular degeneration
  • anti-VEGF
  • monitoring
  • neovascularization
  • ranibizumab
  • treatment

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Fingerprint Dive into the research topics of 'Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab'. Together they form a unique fingerprint.

Cite this